340B Drug Pricing Program
The U.S. Senate Committee on Health, Education, Labor and Pensions Oct. 23 will hold a hearing titled, “The 340B Program: Examining Its Growth and Impact on Patients.”
Senate HELP Committee to hold hearing on 340B program
For nearly 30 years, the 340B Drug Pricing Program has provided financial help to safety-net hospitals to manage rising prescription drug costs. Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted…
In 2022, tax-exempt hospitals participating in the 340B Drug Pricing Program provided nearly $100 billion in total benefits to their communities, according to a new AHA report.
In 2022, tax-exempt hospitals participating in the 340B Drug Pricing Program provided nearly $100 billion in total benefits to their communities, according to a new AHA report.
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s law protecting 340B pricing for contract pharmacy arrangements. The two companies were also denied a preliminary injunction in Maine last…
AHA, others file amicus brief against Novartis motion to block Rhode Island 340B Contract Pharmacy Law -9-16-2025.
AHA, others file amicus brief against AbbVie’s motion to block Rhode Island’s 340B Contract Pharmacy Law-9-18-2025.
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s estimates, and HRSA should delay the program’s implementation, the AHA today told the agency.
In a letter responding to HRSA’s information collection request regarding the expected costs of its 340B Rebate Model Pilot Program, the AHA said 340B hospitals indicated that the operational costs associated with the rebate model could range from $150,000 to over $500,000 per hospital.